Effect of tegoprazan on temporal variability of platelet reactivity in patients treated with clopidogrel after coronary stenting

Abstract

Background/Aims: Data on the interactions between clopidogrel and tegoprazan are limited. We compared the effects of tegoprazan and proton-pump inhibitors (PPIs) on platelet reactivity. Methods: Using database data from March 2020 to January 2023, we retrospectively evaluated 262 patients who were taking either tegoprazan (n = 107) or PPIs (n = 155) combined with dual antiplatelet therapy, including aspirin and clopidogrel, after percutaneous coronary intervention. Platelet reactivity was assessed using VerifyNow P2Y12 assays. Results: Platelet reaction unit (PRU) values at 3 (157 +/- 8 vs. 162 +/- 6, p = 0.659), 6 (167 +/- 9 vs. 158 +/- 7, p = 0.370), and 12 months (155 +/- 10 vs. 164 +/- 7, p = 0.448) were similar between groups. The prevalence of high on-treatment platelet reactivity, defined as >= 253 PRU, was also similar between the groups at 3 (10.3% vs. 10.2%, p = 0.976), 6 (7.0% vs. 8.2%, p = 1.000), and 12 months (4.3% vs. 9.0%, p = 0.503). Conclusions: There was no significant difference in platelet reactivity between the tegoprazan and PPI groups in patients undergoing PCI and receiving dual antiplatelet therapy with clopidogrel.